Compare Apple Inc (AAPL) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs Moderna, Inc. — how do they compare? Apple Inc trades at $304.35 (market cap $4.50T), while Moderna, Inc. trades at $60.66 (market cap $23.88B). The key difference: Apple Inc is far larger — about 188.4× Moderna, Inc.'s market cap, and Apple Inc pays a 0.35% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| AAPL | MRNA | |
|---|---|---|
Market Cap | $4.50T | $23.88B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $81.80 |
52-Week Low | $224.90 | $22.36 |
Enterprise Value | $4.52T | $20.03B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal but strong fundamentals including a 26.91% net margin and three consecutive quarterly EPS beats. Recent news highlights AI potential via 2.5 billion devices and a Gemini partnership, though store closures and union disputes present headwinds.
The outlook balances robust earnings growth and cash flow against high valuation multiples and technical weakness. Upside to the $337.63 consensus target exists if AI initiatives accelerate, but competition and macroeconomic pressures remain key risks for investors.
Moderna (MRNA) stock trades at $59.17, up 9.86% recently, with a bullish technical signal and strong institutional buying interest. The company's Q2 2026 earnings beat expectations, and the FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50+ marks a key post-pandemic milestone. However, fundamentals show declining revenue from $18.9B in 2022 to $1.9B in 2025 and persistent net losses, with a negative net income margin of -142.58% in 2025.
The outlook hinges on pipeline execution; while new vaccine approvals and cost-cutting efforts offer growth potential, the stock faces risks from high valuation multiples and ongoing profitability challenges. Analyst consensus is cautious with a $54.33 price target below the current price, reflecting mixed sentiment amid transitional phase uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
